When Communicating Product Risks, FDA Should Involve Firms – AdvaMed
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed is urging FDA to "routinely" consult with manufacturers when developing and evaluating safety-related communications about devices, drugs and other regulated products
You may also be interested in...
FDA Risk Communication Plan May Be Released Within A Month
FDA's strategic plan for ensuring the public receives accurate and balanced information about the risks and benefits of medical products could be released within a month, according to FDA Center for Drug Evaluation and Research Director Janet Woodcock
FDA Risk Communication Plan May Be Released Within A Month
FDA's strategic plan for ensuring the public receives accurate and balanced information about the risks and benefits of medical products could be released within a month, according to FDA Center for Drug Evaluation and Research Director Janet Woodcock
Heart Rhythm Experts Release New Pacer/ICD Lead Management Guidelines
New recommendations from leading heart experts call on physicians, device manufacturers and FDA to do a better job monitoring and managing the safety of pacemaker and implantable defibrillator leads
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: